ReST Therapeutics Inc
ReST Therapeutics is a clinical-stage biotech company dedicated to developing breakthrough therapies for neuropsychiatric disorders, including Alzheimer’s disease and Post-Traumatic Stress Disorder (PTSD). Their mission is to address unmet medical needs through precision medicine, with a focus on neuroprotection and neuroplasticity. They are advancing their flagship drug candidate FENM, which has shown promising preclinical results and is progressing through clinical development, including receiving endorsement from the European Medicine Agency (EMA) to enter First in Human trials.
Industries
Nr. of Employees
small (1-50)
ReST Therapeutics Inc
New Haven, Connecticut, United States, North America
Products
Proprietary fluorinated NMDA receptor antagonist (lead clinical candidate)
A fluorinated small-molecule NMDA receptor channel inhibitor originally developed as an imaging biomarker and progressed as a therapeutic candidate for early intervention in stress-related disorders and neurodegenerative conditions; advanced through preclinical efficacy and safety studies and positioned for first-in-human administration.
Proprietary fluorinated NMDA receptor antagonist (lead clinical candidate)
A fluorinated small-molecule NMDA receptor channel inhibitor originally developed as an imaging biomarker and progressed as a therapeutic candidate for early intervention in stress-related disorders and neurodegenerative conditions; advanced through preclinical efficacy and safety studies and positioned for first-in-human administration.
Services
Collaborative preclinical and translational research partnerships
Partnership engagements with academic and clinical research groups to co-develop preclinical models, run behavioral and biochemical studies, and translate imaging biomarkers into therapeutic development.
Collaborative preclinical and translational research partnerships
Partnership engagements with academic and clinical research groups to co-develop preclinical models, run behavioral and biochemical studies, and translate imaging biomarkers into therapeutic development.
Expertise Areas
- NMDA receptor–targeted small-molecule therapeutics
- Preclinical behavioral neuroscience and pharmacology
- Translational biomarker development and PET-enabled compounds
- Preclinical electrophysiology and in vitro binding assays
Key Technologies
- Subtype-selective NMDA receptor channel inhibition
- Fluorinated small-molecule PET tracer chemistry
- Rodent behavioral assays (fear conditioning, forced swim, extinction learning)
- Radioligand binding assays